Trials / Completed
CompletedNCT04036669
Adipokines as Predictors of Foot Function, Pain, and Disability in Patients With Rheumatoid Arthritis
Foot Bone Mineral Density and Inflammation in Rheumatoid Arthritis
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 160 (actual)
- Sponsor
- King Saud University · Academic / Other
- Sex
- All
- Age
- 35 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
Significant increase in the levels of serum adiponectin, ADA, and hsCRP was reported in all RA patients compared to controls. Compared to patients with early RA, the increase in these markers significantly correlated with disease activity (DAS-ESR), lower f-BMD, radiographic scoring, pain, FFI, and functional limitations in patients with established RA. Adiponectin showed a negative correlation with serum levels of both ADA and hsCRP. By using ROC curve analysis, optimal cut-off values of adiponectin (28.8 µg/ml), ADA (27.3 IU/L), and hsCRP (1.6 mg/L) could be used to estimate early RA in 45 % of the patients. Similarly, using cut-off values of adiponectin (32.8 µg/ml), ADA (26.1 IU/L ml), and hsCRP (2.5 mg/L), established RA could be predicted in 55 % of patients with 98-99% accuracy.
Detailed description
The present study attempts to evaluate the efficacy of adiponectin, ADA, and foot bone mineral density (fBMD) as predictors of the disease progression in patients with rheumatoid arthritis. A total of 80 RA patients and eighty age and sex-matched healthy controls were included in this study.
Conditions
Timeline
- Start date
- 2014-02-20
- Primary completion
- 2015-04-30
- Completion
- 2015-05-30
- First posted
- 2019-07-30
- Last updated
- 2019-07-30
Source: ClinicalTrials.gov record NCT04036669. Inclusion in this directory is not an endorsement.